Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVATAR: Anticoagulation Strategy Post-TAVI
NCT02735902Phase 4Completed
- Sponsor
- CHU Nîmes
- Start
- Jun 2017
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of apixaban and edoxaban in Atrial fibrillation (AFib) and thromboembolism (2 arms), sponsored by CHU Nîmes. Primary endpoint: Net Clinical Benefit (Composite of death, MI, stroke, valve thrombosis, major bleeding) at 12 months. Started Jun 2017; status: completed.
02
Drugs
apixabanedoxaban
03
Conditions
Atrial fibrillation (AFib)thromboembolism
Beyond the preview
Go deeper on NCT02735902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02735902.